Medistim

Regulatory Filings • Jun 25, 2014

Medistim has received clearance from Russia for sale of VeriQ C

Medistim has received clearance from Russia for sale of VeriQ C

(Oslo, June 25th, 2014) Medistim ASA (OSE: MEDI), a

Norwegian company that develops and commercializes

medical equipment for use within cardiac, vascular

and transplant surgery, announces that they have

received clearance from health authorities in Russia

for sale of its product VeriQ C.

VeriQ C is Medistim's most advanced intraoperative

systems for quality assessment used during coronary

artery bypass grafting (CABG). The system combines

state-of-art transit time blood flow measurements

(TTFM) with a new ultrasound imaging modality. By

using ultrasound imaging, it will become easier for

the surgeon to plan, optimize and assess quality of

the surgical procedure. VeriQ C is a unique tool that

can contribute to improved surgical precision and

quality, which may ultimately provide better outcomes

for the patients.

In addition to CABG, the VeriQ C may be applied in

other surgical areas, such as valve surgery, surgery

of congenital heart defects, transplant surgery and

vascular surgery.

Medistim has already obtained clearance from the Food

and Drug Administration in the US (FDA), the CE

certificate in Europe and the clearance for sale in

Japan and Canada. Medistim is now positioned to sell

the VeriQ C in most markets.

Globally, about 700 000 CABG procedures and 600.000

vascular procedures are being performed every year.

The largest market for Medistim's products is the US,

constituting about 33 % of the global market. Russia

represents an interesting market opportunity for

Medistim with about 26.000 procedures performed per

year, and a projected growth of 8 % per year. With

the clearance from the Russian health authorities in

place, the first sale of VeriQ C in Russia was sold

to the Cardiac Center in Kemerovo.

For more information, contact:

President & CEO, Kari E. Krogstad, Medistim ASA

Tel: + 47 918 38 110

Email: kari.krogstad@Medistim.com

CFO, Thomas Jakobsen, Medistim ASA

Tel: + 47 906 59 940

Email: thomas.jakobsen@Medistim.com

About Medistim

Medistim was established in 1984, and has a track

record of profitable growth over the past 10 years.

The company is a pioneer within its segment, and

continues to invest in new product development.

Medistim has wholly owned subsidiaries with sales

organizations in the US, Germany, Denmark, UK and

Norway, in addition to the around 50 distributors in

Europe, Asia, Middle East, Africa and South

America. For more information, visit the Medistim

home page: www.Medistim.com

This information is disclosed under Norwegian law

(Verdipapirhandelloven §5-12).